Filing Flows › Incyte (INCY) › Q3 2026
Incyte (INCY) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 29, 2026
Incyte (INCY) reported revenue of $1.6B for the third quarter 2026 (Q3 2026), +14% from a year earlier and -7% from the quarter before. Operating margin was -45.5%, net loss $785M (50.4% of revenue).
Incyte, Q3 2026: revenue $1.6B (+14% year over year), operating margin -45.5%, net loss $785M, operating cash flow −$675M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.6B | -7% | +14% |
| Operating profit | −$708M | -201% | -260% |
| Net earnings | −$785M | -234% | -285% |
| Operating cash flow | −$675M | -233% | -221% |
What changed
Revenue was $1.6B in Q3 2026, up 14% year over year and down 7% from the previous quarter. JAKAFI was the largest line at 53% of revenue. OPZELURA added $0.07B year over year (up 36%), 35% of the total change. ICLUSIG declined 11%.
Operating costs exceeded revenue by $0.71B, an operating margin of -45.5%. Total costs grew 146% against revenue growth of 14%. The quarter ended with a net loss of $0.78B, after a profit of $0.59B the previous quarter.
Operating cash flow was −$0.68B. Non-cash charges added back $0.02B of depreciation and amortization and $0.07B of share-based compensation.
Questions
What was Incyte's revenue in the third quarter 2026?
Incyte (INCY) reported revenue of $1.6B for the third quarter 2026 (Q3 2026), +14% from a year earlier and -7% from the quarter before.
Was Incyte profitable in the third quarter 2026?
Operating loss was $708M (-45.5% of revenue) and net loss $785M.
Source: Incyte 10-Q on SEC EDGAR.